Biohaven Ltd. Other Nonoperating Income (Expense)
Biohaven Ltd. (BHVN) reported Other Nonoperating Income (Expense) of $8.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Income Statement › Other Income
us-gaap:OtherNonoperatingIncomeExpense · last filed 2026-03-02
- Biohaven Ltd. other nonoperating income (expense) for the quarter ending 2024-03-31 was $4.30M, a 47.69% decline year-over-year.
- Biohaven Ltd. other nonoperating income (expense) for the quarter ending 2023-12-31 was $7.74M.
- Biohaven Ltd. other nonoperating income (expense) for the quarter ending 2023-09-30 was $4.69M.
- Biohaven Ltd. other nonoperating income (expense) for the quarter ending 2023-06-30 was $5.84M.
- Biohaven Ltd. other nonoperating income (expense) for fiscal 2025 was $8.00M, a 79.71% decline from fiscal 2024.
- Biohaven Ltd. other nonoperating income (expense) for fiscal 2024 was $39.42M, a 48.77% increase from fiscal 2023.
- Biohaven Ltd. other nonoperating income (expense) for fiscal 2023 was $26.50M.
- Biohaven Ltd. other nonoperating income (expense) for fiscal 2022 was -$1.91M, a 257.90% decline from fiscal 2021.
| Period end | Other Nonoperating Income (Expense) 3 month | Other Nonoperating Income (Expense) 6 month | Other Nonoperating Income (Expense) 9 month | Other Nonoperating Income (Expense) 12 month |
|---|---|---|---|---|
| 2025-12-31 | $8.00M 10-K · filed 2026-03-02 | |||
| 2024-12-31 | $39.42M 10-K · filed 2026-03-02 | |||
| 2024-03-31 | $4.30M 10-Q · filed 2024-05-09 | $12.05M derived: sum of 2 quarters · filed 2026-03-02 | $16.73M derived: sum of 3 quarters · filed 2026-03-02 | $22.58M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $7.74M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $12.43M derived: sum of 2 quarters · filed 2026-03-02 | $18.27M derived: sum of 3 quarters · filed 2026-03-02 | $26.50M 10-K · filed 2026-03-02 |
| 2023-09-30 | $4.69M 10-Q · filed 2023-11-14 | $10.53M derived: sum of 2 quarters · filed 2023-11-14 | $18.76M 10-Q · filed 2023-11-14 | $16.92M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $5.84M 10-Q · filed 2023-07-31 | $14.07M 10-Q · filed 2023-07-31 | $12.23M derived: sum of 3 quarters · filed 2025-03-03 | $12.23M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $8.23M 10-Q · filed 2024-05-09 | $6.39M derived: sum of 2 quarters · filed 2025-03-03 | $6.39M derived: sum of 3 quarters · filed 2025-03-03 | $6.32M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | -$1.84M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$1.84M derived: sum of 2 quarters · filed 2025-03-03 | -$1.91M derived: sum of 3 quarters · filed 2025-03-03 | -$1.91M 10-K · filed 2025-03-03 |
| 2022-09-30 | $0.00 10-Q · filed 2023-11-14 | -$67.00K derived: sum of 2 quarters · filed 2023-11-14 | -$71.00K 10-Q · filed 2023-11-14 | $1.38M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | -$67.00K 10-Q · filed 2023-07-31 | -$71.00K 10-Q · filed 2023-07-31 | $1.38M derived: sum of 3 quarters · filed 2024-02-29 | $1.38M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | -$4.00K 10-Q · filed 2023-05-12 | $1.45M derived: sum of 2 quarters · filed 2024-02-29 | $1.45M derived: sum of 3 quarters · filed 2024-02-29 | |
| 2021-12-31 | $1.45M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $1.45M derived: sum of 2 quarters · filed 2024-02-29 | $1.21M 10-K · filed 2024-02-29 | |
| 2021-09-30 | -$5.00K 10-Q · filed 2022-11-09 | -$245.00K 10-Q · filed 2022-11-09 | ||
| 2020-12-31 | $0.00 10-K · filed 2023-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |